Seeking Alpha

Transcept rejects Retrophin proposal

  • Transcept Pharmaceuticals (TSPT) formally rejects Retrophin's (RTRX.PK) $4/share takeout bid.
  • TSPT says the deal "is not in the best interest of shareholders." (PR)
  • The company previously rejected a lower offer from Retrophin.
  • TSPT +5% AH
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)